Small Heterodimer Partner-Targeting Therapy Inhibits Systemic Inflammatory Responses through Mitochondrial Uncoupling Protein 2

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yang, Chul Su ^a   Yuk, Jae Min ^a   Kim, Jwa Jin ^a   Hwang, Jung Hwan ^b   Lee, Chul Ho ^b   Kim, Jin Man ^a   Oh, Goo Taeg ^c   Choi, Hueng Sik ^d   Jo, Eun Kyeong ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Ewha Womans University   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOCHONDRIAL PROTEIN; ORPHAN NUCLEAR RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE LKB1; REACTIVE OXYGEN METABOLITE; SMALL HETERODIMER PARTNER; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL; SYSTEMIC DISEASE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; FENOFIBRATE; HEK293 CELLS; HUMANS; INFLAMMATION; ION CHANNELS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; PPAR ALPHA; PROTECTIVE AGENTS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; UBIQUITINATION;

EID: 84877956229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063435     Document Type: Article

References (58)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
2. Pardee K, Necakov AS, Krause H, (2011) Nuclear Receptors: Small Molecule Sensors that Coordinate Growth, Metabolism and Reproduction. Subcell Biochem 52: 123-153.
3. Lee YS, Chanda D, Sim J, Park YY, Choi HS, (2007) Structure and function of the atypical orphan nuclear receptor small heterodimer partner. Int Rev Cytol 261: 117-158.
4. Chanda D, Park JH, Choi HS, (2008) Molecular basis of endocrine regulation by orphan nuclear receptor Small Heterodimer Partner. Endocr J 55: 253-268.
5. Burris TP, Busby SA, Griffin PR, (2012) Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 19: 51-59.
6. Båvner A, Sanyal S, Gustafsson JA, Treuter E, (2005) Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrinol Metab 16: 478-488.
7. Garruti G, Wang HH, Bonfrate L, de Bari O, Wang DQ, et al. (2012) A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways. J Lipids 2012: 304292.
8. Zhang Y, Hagedorn CH, Wang L, (2011) Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 1812: 893-908.
9. Kim YD, Park KG, Lee YS, Park YY, Kim DK, et al. (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57: 306-314.
10. Chanda D, Li T, Song KH, Kim YH, Sim J, et al. (2009) Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptor small heterodimer partner in primary hepatocytes. J Biol Chem 284: 28510-28521.
11. Chanda D, Lee CH, Kim YH, Noh JR, Kim DK, et al. (2009) Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology 50: 880-892.
12. Chanda D, Kim SJ, Lee IK, Shong M, Choi HS, (2008) Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression. Am J Physiol Endocrinol Metab 295: E368-E379.
13. Marshall J, (2001) Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29: S99-S106.
14. Asquith M, Powrie F, (2010) An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med 207: 1573-1577.
15. Pascual G, Glass CK, (2006) Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17: 321-327.
16. Glass CK, Saijo K, (2010) Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 10: 365-376.
17. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D, (2007) Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27: 2606-2611.
18. Yuk JM, Shin DM, Lee HM, Kim JJ, Kim SW, et al. (2011) The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat Immunol 12: 742-751.
19. Mailloux RJ, Harper ME, (2011) Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radic Biol Med 51: 1106-1115.
20. Diano S, Horvath TL, (2012) Mitochondrial uncoupling protein 2 (UCP2) in glucose and lipid metabolism. Trends Mol Med 18: 52-58.
21. Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, et al. (2000) Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 26: 435-439.
22. Emre Y, Hurtaud C, Karaca M, Nubel T, Zavala F, et al. (2007) Role of uncoupling protein UCP2 in cell-mediated immunity: how macrophage-mediated insulitis is accelerated in a model of autoimmune diabetes. Proc Natl Acad Sci U S A 104: 19085-19090.
23. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, et al. (2002) Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2: 721-731.
24. Yang CS, Lee DS, Song CH, An SJ, Li S, et al. (2007) Roles of peroxiredoxin II in the regulation of proinflammatory responses to LPS and protection against endotoxin-induced lethal shock. J Exp Med 204: 583-594.
25. Fic E, Kedracka-Krok S, Jankowska U, Pirog A, Dziedzicka-Wasylewska M, (2010) Comparison of protein precipitation methods for various rat brain structures prior to proteomic analysis. Electrophoresis 31: 3573-3579.
26. Roff M, Thompson J, Rodriguez MS, Jacque JM, Baleux F, et al. (1996) Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem 271: 7844-7850.
27. Straus DS, Glass CK, (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28: 551-558.
28. Carling D, Sanders MJ, Woods A, (2008) The regulation of AMP-activated protein kinase by upstream kinases. Int J Obes (Lond) 32: S55-S59.
29. Carlson CA, Kim KH, (1973) Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem 248: 378-380.
30. Kładna A, Aboul-Enein HY, Kruk I, Lichszteld K, Michalska T, (2006) Scavenging of reactive oxygen species by some nonsteroidal anti-inflammatory drugs and fenofibrate. Biopolymers 82: 99-105.
31. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, et al. (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208: 519-533.
32. Bai Y, Onuma H, Bai X, Medvedev AV, Misukonis M, et al. (2005) Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production. J Biol Chem 280: 19062-19069.
33. Gouni-Berthold I, Krone W, (2005) Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis. Curr Drug Targets Cardiovasc Haematol Disord 5: 513-523.
34. Keating GM, Croom KF, (2007) Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67: 121-153.
35. McKeage K, Keating GM, (2011) Fenofibrate: a review of its use in dyslipidaemia. Drugs 71: 1917-1946.
36. Wong TY, Simó R, Mitchell P, (2012) Fenofibrate- a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 154: 6-12.
37. Sehgal N, Kumawat KL, Basu A, Ravindranath V, (2012) Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection. PLoS One 7: e35427.
38. Goto M, (2010) A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol 20: 238-243.
39. Mansouri RM, Baugé E, Staels B, Gervois P, (2008) Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology 149: 3215-3223.
40. Patel NS, di Paola R, Mazzon E, Britti D, Thiemermann C, et al. (2009) Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther 328: 635-643.
41. Hiukka A, Maranghi M, Matikainen N, Taskinen MR, (2010) PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 6: 454-463.
42. Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, et al. (2011) Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 31: 1573-1579.
43. Lage R, Diéguez C, Vidal-Puig A, López M, (2008) AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14: 539-549.
44. Salminen A, Hyttinen JM, Kaarniranta K, (2011) AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 89: 667-676.
45. Nath N, Giri S, Prasad R, Salem ML, Singh AK, et al. (2005) 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol 175: 566-574.
46. Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, et al. (2008) Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295: L497-L504.
47. Bai A, Ma AG, Yong M, Weiss CR, Ma Y, et al. (2010) AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol 80: 1708-1717.
48. Myerburg MM, King JD Jr, Oyster NM, Fitch AC, Magill A, et al. (2010) AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 42: 676-684.
49. Yang Z, Kahn BB, Shi H, Xue BZ, (2010) Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 285: 19051-19059.
50. Kato Y, Koide N, Komatsu T, Tumurkhuu G, Dagvadorj J, et al. (2010) Metformin attenuates production of nitric oxide in response to lipopolysaccharide by inhibiting MyD88-independent pathway. Horm Metab Res 42: 632-636.
51. Tsoyi K, Jang HJ, Nizamutdinova IT, Kim YM, Lee YS, et al. (2011) Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 162: 1498-1508.
52. Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K, (2011) Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 60: 513-522.
53. Chen WL, Chen YL, Chiang YM, Wang SG, Lee HM, (2012) Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway. Biochem Pharmacol 84: 522-531.
54. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, et al. (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12: 222-230.
55. Zhou R, Yazdi AS, Menu P, Tschopp J, (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225.
56. Naik E, Dixit VM, (2011) Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med 208: 417-420.
57. Leloup C, Casteilla L, Carrière A, Galinier A, Benani A, et al. (2011) Balancing mitochondrial redox signaling: a key point in metabolic regulation. Antioxid Redox Signal 14: 519-530.
58. Zhang Y, Soto J, Park K, Viswanath G, Kuwada S, et al. (2010) Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth. Mol Cell Biol 30: 1341-1356.